Annual CFF
$28.46 M
+$20.11 M+240.80%
December 31, 2023
Summary
- As of February 7, 2025, ZVRA annual cash flow from financing activities is $28.46 million, with the most recent change of +$20.11 million (+240.80%) on December 31, 2023.
- During the last 3 years, ZVRA annual CFF has risen by +$25.73 million (+939.21%).
- ZVRA annual CFF is now -74.83% below its all-time high of $113.11 million, reached on December 31, 2021.
Performance
ZVRA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$64.77 M
+$49.44 M+322.47%
September 30, 2024
Summary
- As of February 7, 2025, ZVRA quarterly cash flow from financing activities is $64.77 million, with the most recent change of +$49.44 million (+322.47%) on September 30, 2024.
- Over the past year, ZVRA quarterly CFF has increased by +$59.76 million (+1194.26%).
- ZVRA quarterly CFF is now -12.82% below its all-time high of $74.29 million, reached on March 1, 2021.
Performance
ZVRA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$86.32 M
+$38.51 M+80.54%
September 30, 2024
Summary
- As of February 7, 2025, ZVRA TTM cash flow from financing activities is $86.32 million, with the most recent change of +$38.51 million (+80.54%) on September 30, 2024.
- Over the past year, ZVRA TTM CFF has increased by +$57.85 million (+203.25%).
- ZVRA TTM CFF is now -28.69% below its all-time high of $121.05 million, reached on March 1, 2016.
Performance
ZVRA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ZVRA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +240.8% | +1194.3% | +203.3% |
| 3 y3 years | +939.2% | +1194.3% | +203.3% |
| 5 y5 years | +1.6% | +1194.3% | +203.3% |
ZVRA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -74.8% | +240.8% | at high | +1468.4% | -23.7% | +2591.1% |
| 5 y | 5-year | -74.8% | +939.2% | -12.8% | +1468.4% | -25.6% | +2591.1% |
| alltime | all time | -74.8% | >+9999.0% | -12.8% | +1468.4% | -28.7% | +2591.1% |
Zevra Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $64.77 M(+322.5%) | $86.32 M(+80.5%) |
| Jun 2024 | - | $15.33 M(+1159.7%) | $47.81 M(+43.0%) |
| Mar 2024 | - | $1.22 M(-75.7%) | $33.43 M(+17.5%) |
| Dec 2023 | $28.46 M(+240.8%) | $5.00 M(-80.9%) | $28.46 M(+22.7%) |
| Sep 2023 | - | $26.26 M(+2661.2%) | $23.20 M(-769.6%) |
| Jun 2023 | - | $951.00 K(-125.4%) | -$3.46 M(-137.1%) |
| Mar 2023 | - | -$3.75 M(+1359.1%) | $9.34 M(+11.8%) |
| Dec 2022 | $8.35 M(-92.6%) | -$257.00 K(-37.2%) | $8.35 M(+45.5%) |
| Sep 2022 | - | -$409.00 K(-103.0%) | $5.74 M(-29.1%) |
| Jun 2022 | - | $13.75 M(-390.5%) | $8.09 M(-76.3%) |
| Mar 2022 | - | -$4.73 M(+64.9%) | $34.09 M(-69.9%) |
| Dec 2021 | $113.11 M(+4029.6%) | - | - |
| Dec 2021 | - | -$2.87 M(-247.8%) | $113.11 M(-2.4%) |
| Sep 2021 | - | $1.94 M(-95.1%) | $115.93 M(+1.7%) |
| Jun 2021 | - | $39.75 M(-46.5%) | $113.94 M(+49.9%) |
| Mar 2021 | - | $74.29 M(<-9900.0%) | $76.01 M(+2675.1%) |
| Dec 2020 | $2.74 M(-44.5%) | -$46.00 K(-9.8%) | $2.74 M(+12.5%) |
| Sep 2020 | - | -$51.00 K(-102.8%) | $2.44 M(-38.0%) |
| Jun 2020 | - | $1.82 M(+78.0%) | $3.93 M(+19.5%) |
| Mar 2020 | - | $1.02 M(-391.4%) | $3.29 M(-33.4%) |
| Dec 2019 | $4.94 M | -$350.00 K(-124.3%) | $4.94 M(-82.7%) |
| Sep 2019 | - | $1.44 M(+22.7%) | $28.55 M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | $1.18 M(-56.0%) | $27.90 M(-0.1%) |
| Mar 2019 | - | $2.67 M(-88.5%) | $27.94 M(-0.3%) |
| Dec 2018 | $28.02 M(<-9900.0%) | $23.27 M(+2852.4%) | $28.02 M(+494.1%) |
| Sep 2018 | - | $788.00 K(-35.3%) | $4.72 M(+21.4%) |
| Jun 2018 | - | $1.22 M(-55.7%) | $3.89 M(+48.9%) |
| Mar 2018 | - | $2.75 M(-7334.2%) | $2.61 M(-1385.2%) |
| Dec 2017 | -$203.00 K(-100.3%) | -$38.00 K(-9.5%) | -$203.00 K(-67.7%) |
| Sep 2017 | - | -$42.00 K(-30.0%) | -$628.00 K(-75.8%) |
| Jun 2017 | - | -$60.00 K(-4.8%) | -$2.59 M(+3.2%) |
| Mar 2017 | - | -$63.00 K(-86.4%) | -$2.51 M(-104.1%) |
| Dec 2016 | $61.16 M(-0.5%) | -$463.00 K(-76.9%) | $61.16 M(+1.3%) |
| Sep 2016 | - | -$2.01 M(<-9900.0%) | $60.38 M(-2.4%) |
| Jun 2016 | - | $20.00 K(-100.0%) | $61.84 M(-48.9%) |
| Mar 2016 | - | $63.61 M(-5205.3%) | $121.05 M(+96.9%) |
| Dec 2015 | $61.47 M(+167.2%) | -$1.25 M(+127.4%) | $61.47 M(+0.9%) |
| Sep 2015 | - | -$548.00 K(-100.9%) | $60.94 M(-0.8%) |
| Jun 2015 | - | $59.23 M(+1368.2%) | $61.45 M(+127.1%) |
| Mar 2015 | - | $4.03 M(-327.4%) | $27.06 M(+17.6%) |
| Dec 2014 | $23.00 M(+507.3%) | -$1.77 M(+4226.8%) | $23.00 M(-7.2%) |
| Sep 2014 | - | -$41.00 K(-100.2%) | $24.78 M(-0.2%) |
| Jun 2014 | - | $24.84 M(<-9900.0%) | $24.82 M(<-9900.0%) |
| Mar 2014 | - | -$22.00 K | -$22.00 K |
| Dec 2013 | $3.79 M | - | - |
FAQ
- What is Zevra Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Zevra Therapeutics?
- What is Zevra Therapeutics annual CFF year-on-year change?
- What is Zevra Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Zevra Therapeutics?
- What is Zevra Therapeutics quarterly CFF year-on-year change?
- What is Zevra Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Zevra Therapeutics?
- What is Zevra Therapeutics TTM CFF year-on-year change?
What is Zevra Therapeutics annual cash flow from financing activities?
The current annual CFF of ZVRA is $28.46 M
What is the all time high annual CFF for Zevra Therapeutics?
Zevra Therapeutics all-time high annual cash flow from financing activities is $113.11 M
What is Zevra Therapeutics annual CFF year-on-year change?
Over the past year, ZVRA annual cash flow from financing activities has changed by +$20.11 M (+240.80%)
What is Zevra Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ZVRA is $64.77 M
What is the all time high quarterly CFF for Zevra Therapeutics?
Zevra Therapeutics all-time high quarterly cash flow from financing activities is $74.29 M
What is Zevra Therapeutics quarterly CFF year-on-year change?
Over the past year, ZVRA quarterly cash flow from financing activities has changed by +$59.76 M (+1194.26%)
What is Zevra Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ZVRA is $86.32 M
What is the all time high TTM CFF for Zevra Therapeutics?
Zevra Therapeutics all-time high TTM cash flow from financing activities is $121.05 M
What is Zevra Therapeutics TTM CFF year-on-year change?
Over the past year, ZVRA TTM cash flow from financing activities has changed by +$57.85 M (+203.25%)